Literature DB >> 24998081

Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?

Deepak L Bhatt1, Matthew A Cavender2.   

Abstract

Entities:  

Keywords:  diabetes; heart failure; hospitalization; mortality; sitagliptin

Mesh：

Substances：

Year:  2014        PMID： 24998081     DOI： 10.1016/j.jchf.2014.05.005

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN： 2213-1779            Impact factor:   12.035


× No keyword cloud information.
  14 in total

Review 1.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

Review 2.  Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.

Authors:  Ersilia M DeFilippis; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2016-06

Review 3.  DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.

Authors:  Chayakrit Krittanawong; Andrew Xanthopoulos; Takeshi Kitai; Natalia Branis; HongJu Zhang; Marrick Kukin
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

4.  SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.

Authors:  Rhanderson Cardoso; Fabrissio P Graffunder; Caique M P Ternes; Amanda Fernandes; Ana V Rocha; Gilson Fernandes; Deepak L Bhatt
Journal:  EClinicalMedicine       Date:  2021-06-05

5.  Unbiased omics identifies mechanistic regulators of calcific aortic valve disease.

Authors:  Maximillian A Rogers; Elena Aikawa
Journal:  Eur Heart J       Date:  2021-08-07       Impact factor: 35.855

Review 6.  Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.

Authors:  Jixin Zhong; Quan Gong; Aditya Goud; Srividya Srinivasamaharaj; Sanjay Rajagopalan
Journal:  J Diabetes Res       Date:  2015-05-14       Impact factor: 4.011

7.  Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts.

Authors:  Tsung-Ming Lee; Wei-Ting Chen; Chen-Chia Yang; Shinn-Zong Lin; Nen-Chung Chang
Journal:  J Cell Mol Med       Date:  2014-11-11       Impact factor: 5.310

8.  Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients.

Authors:  Larry A Weinrauch; George Bayliss; Alissa R Segal; Jiankang Liu; Eric Wisniewski; John A D'Elia
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-03-02       Impact factor: 3.738

Review 9.  DPP4 in Diabetes.

Authors:  Diana Röhrborn; Nina Wronkowitz; Juergen Eckel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561

10.  Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.

Authors:  Yi-Chih Hung; Che-Chen Lin; Wei-Lun Huang; Man-Ping Chang; Ching-Chu Chen
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.